Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Cancer statistics, 2018

Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632

Cancer statistics, 2016

Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Cancer Statistics, 2017.

Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

Stem cells, cancer, and cancer stem cells

Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,839

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

Cancer immunoediting: from immunosurveillance to tumor escape

Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

STATs in cancer inflammation and immunity: a leading role for STAT3

Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229

Tumour heterogeneity and resistance to cancer therapies

Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846

Mechanisms of type-I- and type-II-interferon-mediated signalling

Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770

Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences

Raj, A., & van Oudenaarden, A. (2008) · Cell · doi:10.1016/j.cell.2008.09.050 · Cited by 2,593

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V. G., Liszkay, G., Maio, M., Mandalà, M., Демидов, Л. В., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,115

Intra-tumour heterogeneity: a looking glass for cancer?

Marusyk, A., Almendro, V., & Polyák, K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3261 · Cited by 2,058

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942

Efficient tumour formation by single human melanoma cells

Quintana, E., Shackleton, M. J., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,836

Chemokine signaling via the CXCR2 receptor reinforces senescence

Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548

Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465

Identification of cells initiating human melanomas

Schatton, T., Murphy, G. F., Frank, N. Y., Yamaura, K., Waaga-Gasser, A. M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L. M., Weishaupt, C., et al. (2008) · Nature · doi:10.1038/nature06489 · Cited by 1,449

IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy

Ivashkiv, L. B. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,418

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337

Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302

Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Schachter, J., Ribas, A., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,251

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216

Cellular Heterogeneity: Do Differences Make a Difference?

Altschuler, S. J., & Wu, L. F. (2010) · Cell · doi:10.1016/j.cell.2010.04.033 · Cited by 1,214

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

Wang, T., Niu, G., Kortylewski, M., Burdelya, L. G., Shain, K. H., Zhang, S., Bhattacharya, R., Gabrilovich, D. I., Heller, R. F., Coppola, D., et al. (2003) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,182

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147

Senescence in tumours: evidence from mice and humans

Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069

Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis

Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M., & Sorger, P. K. (2009) · Nature · doi:10.1038/nature08012 · Cited by 1,023

Cancer stem cells: mirage or reality?

Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009) · Nature Medicine · doi:10.1038/nm0909-1010 · Cited by 996

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944

From melanocytes to melanomas

Shain, A. H., & Bastian, B. C. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.37 · Cited by 944

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938

Antitumour actions of interferons: implications for cancer therapy

Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.14 · Cited by 920

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888

Identification of essential genes for cancer immunotherapy

Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771

Tumor metastasis: moving new biological insights into the clinic

Wan, L., Pantel, K., & Kang, Y. (2013) · Nature Medicine · doi:10.1038/nm.3391 · Cited by 763

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730

T-helper-1-cell cytokines drive cancer into senescence

Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx176 · Cited by 690

Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors

Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

Landsberg, J., Sirokay, J. D., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 652

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 641

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639

Clonal competition with alternating dominance in multiple myeloma

Keats, J. J., Chesi, M., Egan, J. B., Garbitt, V. M., Palmer, S. E., Braggio, E., Wier, S. V., Blackburn, P. R., Baker, A. S., Dispenzieri, A. A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405985 · Cited by 636

Stochasticity and Cell Fate

Losick, R. M., & Desplan, C. (2008) · Science · doi:10.1126/science.1147888 · Cited by 627

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity

Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 618

Dynamic Proteomics of Individual Cancer Cells in Response to a Drug

Cohen, A., Geva‐Zatorsky, N., Eden, E., Frenkel‐Morgenstern, M., Issaeva, I., Sigal, A., Milo, R., Cohen‐Saidon, C., Liron, Y., Kam, Z., et al. (2008) · Science · doi:10.1126/science.1160165 · Cited by 611

The Two Faces of Interferon-γ in Cancer

Zaidi, M. R., & Merlino, G. T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 594

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature

Hoek, K. S., Schlegel, N. C., Brafford, P. A., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., et al. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00322.x · Cited by 579

Variability and memory of protein levels in human cells

Sigal, A., Milo, R., Cohen, A., Geva‐Zatorsky, N., Klein, Y., Liron, Y., Rosenfeld, N., Danon, T., Perzov, N., & Alon, U. S. (2006) · Nature · doi:10.1038/nature05316 · Cited by 576

Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective

Huang, S., Ernberg, I. T., & Kauffman, S. A. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.07.003 · Cited by 572

Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon

Gogas, H. J., Ioannovich, J. D., Dafni, U. G., Stauropoulou-Giokas, C., Frangia, K. B., Tsoutsos, D. A., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 565

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O. O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 553

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez‐Canales, J., Wistuba, I. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 540

Prognostic significance of autoimmunity during treatment of melanoma with interferon

Krauze, M. T., Tarhini, A. A., Gogas, H. J., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507

Therapy-induced tumour secretomes promote resistance and tumour progression

Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M., Wiesner, T., Rosen, N. X., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 503

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

Yokoyama, S., Woods, S. L., Boyle, G. M., Aoude, L. G., MacGregor, S., Zismann, V., Gartside, M. G., Cust, A. E., Haq, R., Harland, M., et al. (2011) · Nature · doi:10.1038/nature10630 · Cited by 498

Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours

Brock, A., Chang, H. H., & Huang, S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2556 · Cited by 494

Acquired resistance to immunotherapy and future challenges

Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.2 · Cited by 470

Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers

Cleary, A. S., Leonard, T. L., Gestl, S. A., & Gunther, E. J. (2014) · Nature · doi:10.1038/nature13187 · Cited by 461

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature · doi:10.1038/nature12688 · Cited by 452

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

Nowicki, T. S., Hu‐Lieskovan, S., & Ribas, A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000303 · Cited by 408

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Yan, L., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 403

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395

Resistance to BRAF-targeted therapy in melanoma

Sullivan, R. J., & Flaherty, K. T. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.019 · Cited by 386

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

Zingg, D., Arenas-Ramirez, N., Şahin, D., Rosalia, R. A., Antunes, A. T., Häusel, J., Sommer, L., & Boyman, O. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.007 · Cited by 339

MITF in melanoma: mechanisms behind its expression and activity

Hartman, M. L., & Czyż, M. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1791-0 · Cited by 336

Cancer and the Immune System: Basic Concepts and Targets for Intervention

Pardoll, D. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 312

Non-Darwinian dynamics in therapy-induced cancer drug resistance

Pisco, A. O., Brock, A., Zhou, J., Moor, A. E., Mojtahedi, M., Jackson, D. A., & Huang, S. (2013) · Nature Communications · doi:10.1038/ncomms3467 · Cited by 302

Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me’

Pisco, A. O., & Huang, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.146 · Cited by 294

Interferon-γ links ultraviolet radiation to melanomagenesis in mice

Zaidi, M. R., Davis, S., Noonan, F. P., Graff-Cherry, C., Hawley, T. S., Walker, R. L., Feigenbaum, L., Fuchs, E., Lyakh, L., Young, H. A., et al. (2011) · Nature · doi:10.1038/nature09666 · Cited by 293

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

Kammertoens, T., Friese, C., Arina, A., Idel, C., Briesemeister, D., Rothe, M., Ivanov, A., Szymborska, A., Patone, G., Kunz, S., et al. (2017) · Nature · doi:10.1038/nature22311 · Cited by 279

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

Minn, A. J., & Wherry, E. J. (2016) · Cell · doi:10.1016/j.cell.2016.03.031 · Cited by 270

Senescent cells develop a parp-1 and nuclear factor-κB-associated secretome (PNAS).

Ohanna, M., Giuliano, S., Bonet, C., Imbert, V., Hofman, V., Zangari, J., Bille, K., Robert, C., Bressac-de Paillerets, B., Hofman, P., et al. (2011) · Genes & Development · doi:10.1101/gad.625811 · Cited by 267

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells

Luca, A. D., Fiorillo, M., Peiris‐Pagès, M., Ózsvári, B., Smith, D. L., Sánchez‐Alvarez, R., Martinez‐Outschoorn, U., Cappello, A. R., Pezzi, V., Lisanti, M. P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4401 · Cited by 262

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanomaPreprint

Falletta, P., Sánchez‐del‐Campo, L., Chauhan, J. S., Effern, M., Kenyon, A., Kershaw, C. J., Siddaway, R., Lisle, R., Freter, R., Daniels, M. J., et al. (2017) · Genes & Development · doi:10.1101/gad.290940.116 · Cited by 260

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

Sucker, A., Zhao, F., Pieper, N., Heeke, C., Maltaner, R., Stadtler, N., Real, B., Bielefeld, N., Howe, S., Weide, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15440 · Cited by 260

MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis

Hémon, P., Jean‐Louis, F., Ramgolam, K., Brignone, C., Viguier, M. A., Bachelez, H., Triebel, F., Charron, D. J., Aoudjit, F., Al‐Daccak, R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002050 · Cited by 253

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 250

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J. C., Rizos, H., & Hersey, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123410 · Cited by 238

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment

Riesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Sirokay, J. D., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 238

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

Zhao, C., Li, H., Lin, H.-J. L., Yang, S., Lin, J., & Liang, G. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.001 · Cited by 237

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 237

Microphthalmia‐associated transcription factor in melanoma development and MAP ‐kinase pathway targeted therapy

Wellbrock, C., & Arozarena, I. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12370 · Cited by 233

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

Su, Y., Wei, W., Robert, L., Xue, M., Tsoi, J., García-Díaz, Á., Moreno, B. H., Kim, J.-W., Ng, R. H., Lee, J. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712064115 · Cited by 231

Cellular Differences in Protein Synthesis Regulate Tissue Homeostasis

Buszczak, M., Signer, R. A. J., & Morrison, S. J. (2014) · Cell · doi:10.1016/j.cell.2014.09.016 · Cited by 224

Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells.

Brown, T. J., Lioubin, M. N., & Marquardt, H. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.9.2977 · Cited by 222

Cancer Stem Cells: Distinct Entities or Dynamically Regulated Phenotypes?

Li, Y.-Q., & Laterra, J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3070 · Cited by 219

Non-genetic cell-to-cell variability and the consequences for pharmacology

Niepel, M., Spencer, S. L., & Sorger, P. K. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.09.015 · Cited by 218

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216

The role of melanogenesis in regulation of melanoma behavior: Melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways

Slominski, A. T., Kim, T.-K., Brożyna, A. A., Janjetović, Z., Brooks, D. L. P., Schwab, L. P., Skobowiat, C., Jóźwicki, W., & Seagroves, T. N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.030 · Cited by 208

Systematic classification of melanoma cells by phenotype‐specific gene expression mapping

Widmer, D. S., Cheng, P. F., Eichhoff, O. M., Belloni, B., Zipser, M. C., Schlegel, N. C., Javelaud, D., Mauviel, A., Dummer, R., & Hoek, K. S. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00986.x · Cited by 195

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comı́n-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 191

Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells

Huang, S. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9435-7 · Cited by 183

Identification and targeting of cancer stem cells

Schatton, T., Frank, N. Y., & Frank, M. H. (2009) · BioEssays · doi:10.1002/bies.200900058 · Cited by 182

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival

Brody, J. R., Costantino, C. L., Berger, A. C., Sato, T., Lisanti, M. P., Yeo, C. J., Emmons, R. V. B., & Witkiewicz, A. K. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8745 · Cited by 179

Microphthalmia Transcription Factor Expression in Cutaneous Benign, Malignant Melanocytic, and Nonmelanocytic Tumors

King, R., Googe, P. B., Weilbaecher, K. N., Mihm, M. C., & Fisher, D. E. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200101000-00005 · Cited by 177

A stress-induced early innate response causes multidrug tolerance in melanoma

Menon, D. R., Das, S. K., Krepler, C., Vultur, A., Rinner, B., Schauer, S., Kashofer, K., Wagner, K., Zhang, G., Rad, E. B., et al. (2014) · Oncogene · doi:10.1038/onc.2014.372 · Cited by 174

Genetic evolution of T-cell resistance in the course of melanoma progression

Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Reinhardt, J., Landsberg, J., Schmid-Burgk, J. L., Ramis, B. B., Bald, T., Glodde, N., Lopez-Ramos, D., Young, A., Ngiow, S. F., Nettersheim, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0395 · Cited by 167

Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy

Zhao, X., & Subramanian, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2379 · Cited by 162

Melanoma Stem Cells: The Dark Seed of Melanoma

Zabierowski, S. E., & Herlyn, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5465 · Cited by 161

UV Signaling Pathways within the Skin

Chen, H., Weng, Q. Y., & Fisher, D. E. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.161 · Cited by 160

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Song, C., Piva, M., Sun, L., Hong, A., Moriceau, G., Kong, X., Zhang, H., Lomeli, S. H., Qian, J., Yu, C. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0401 · Cited by 160

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

Kong, X., Kuilman, T., Shahrabi, A., Boshuizen, J., Kemper, K., Song, J., Niessen, H. W. M., Rozeman, E. A., Foppen, M. H. G., Blank, C. U., et al. (2017) · Nature · doi:10.1038/nature24037 · Cited by 155

Inflammatory cell infiltrates in human melanoma at different stages of tumor progression

Bröcker, E. B., Zwadlo, G., Holzmann, B., Macher, E., & Sorg, C. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410415 · Cited by 153

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00452-4 · Cited by 151

Interferon-γ and Cancer Immunoediting

Dunn, G. P., Ikeda, H., Bruce, A. T., Koebel, C. M., Uppaluri, R., Bui, J. D., Chan, R., Diamond, M. S., White, J. M., Sheehan, K. C. F., et al. (2005) · Immunologic Research · doi:10.1385/ir:32:1-3:231 · Cited by 147

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab1111 · Cited by 143

Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance

Flach, E. H., Rebecca, V. W., Herlyn, M., Smalley, K. S. M., & Anderson, A. R. A. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200421k · Cited by 142

Microphthalmia-Associated Transcription Factor Controls the DNA Damage Response and a Lineage-Specific Senescence Program in Melanomas

Giuliano, S., Cheli, Y., Ohanna, M., Bonet, C., Beuret, L., Bille, K., Loubat, A., Hofman, V., Hofman, P., Ponzio, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2913 · Cited by 135

Tumor Necrosis Factor-α Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited

Gray‐Schopfer, V. C., Karasarides, M., Hayward, R., & Marais, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1880 · Cited by 135

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., López-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1554 · Cited by 134

Interferons and the immunogenic effects of cancer therapy

Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130

Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4

Mo, X., Zhang, H., Preston, S., Martin, K. A., Zhou, B., Vadalia, N., Gamero, A. M., Soboloff, J., Tempera, I., & Zaidi, M. R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1615 · Cited by 125

Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinomas of the head and neck

Snijders, P. J. F., Scholes, A. G. M., Hart, C. A., Jones, A. S., Vaughan, E. D., Woolgar, J. A., Meijer, C. J. L. M., Walboomers, J. M. M., & Field, J. K. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960516)66:4 · Cited by 122

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1

Sims, J. T., Ganguly, S. S., Bennett, H., Friend, J. W., Tepe, J., & Plattner, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055509 · Cited by 121

Vemurafenib Induces Senescence Features in Melanoma Cells

Haferkamp, S., Borst, A., Adam, C., Becker, T. M., Motschenbacher, S., Windhövel, S., Hufnagel, A., Houben, R., & Meierjohann, S. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.6 · Cited by 116

Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens.

Taniguchi, K., Petersson, M., Höglund, P., Kiessling, R. W., Klein, G., & Kärre, K. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3405 · Cited by 114

Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells

Schmitt, M. J., Philippidou, D., Reinsbach, S. E., Margue, C., Wienecke-Baldacchino, A. K., Nashan, D., Behrmann, I., & Kreis, S. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-41 · Cited by 113

NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF

Fane, M. E., Chhabra, Y., Hollingsworth, D. E. J., Simmons, J. L., Spoerri, L., Oh, T. G., Chauhan, J. S., Chin, T., Harris, L., Harvey, T. J., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.013 · Cited by 111

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. F. L., & Wellbrock, C. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs471 · Cited by 110

Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study

Meyskens, F. L., Kopecky, K. J., Taylor, C. W., Noyes, R. D., Tuthill, R. J., Hersh, E. M., Feun, L. G., Doroshow, J. H., Flaherty, L. E., & Sondak, V. K. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.22.1710 · Cited by 109

Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFNγ-Dependent Cell-Cycle Arrest

Matsushita, H., Hosoi, A., Ueha, S., Abe, J., Fujieda, N., Tomura, M., Maekawa, R., Matsushima, K., Ohara, O., & Kakimi, K. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0098 · Cited by 107

IFN-γ signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation

Natarajan, V. T., Ganju, P., Singh, A. K., Vijayan, V., Kirty, K., Yadav, S., Puntambekar, S. S., Bajaj, S., Dani, P. P., Kar, H. K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304988111 · Cited by 106

Cancer Microenvironment and Endoplasmic Reticulum Stress Response

Giampietri, C., Petrungaro, S., Conti, S., Facchiano, A., Filippini, A., & Ziparo, E. (2015) · Mediators of Inflammation · doi:10.1155/2015/417281 · Cited by 106

BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

Smalley, I., Wargo, J. A., Flaherty, K. T., Messina, J. L., & Smalley, K. S. M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.329 · Cited by 105

Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescence

Liu, Y., Hawkins, O. E., Su, Y., Vilgelm, A. E., Sobolik, T., Thu, Y. M., Kantrow, S. M., Splittgerber, R. C., Short, S. P., Amiri, K. I., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201378 · Cited by 104

Different Requirements for Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 in the Regulation of Low Molecular Mass Polypeptide 2 and Transporter Associated with Antigen Processing 1 Gene Expression

Chatterjee‐Kishore, M., Kishore, R., Hicklin, D. J., Marincola, F. M., & Ferrone, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16177 · Cited by 102

How to escape the cancer attractor: Rationale and limitations of multi-target drugs

Huang, S., & Kauffman, S. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.003 · Cited by 98

Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness

Jobe, N. P., Rösel, D., Dvořánková, B., Kodet, O., Lacina, L., Mateu, R., Smetana, K., & Brábek, J. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1433-8 · Cited by 97

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

Young, H. L., Rowling, E. J., Bugatti, M., Giurisato, E., Luheshi, N., Arozarena, I., Acosta, J. C., Kamarashev, J. A., Frederick, D. T., Cooper, Z. A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160855 · Cited by 95

Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway

Sun, X., Shi, B., Zheng, H., Min, L., Yang, J., Li, X., Liao, X., Huang, W., Zhang, M., Xu, S., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0303-9 · Cited by 95

Molecular Basis for the Critical Role of Suppressor of Cytokine Signaling-1 in Melanoma Brain Metastasis

Huang, F.-J., Steeg, P. S., Price, J. E., Chiu, W., Chou, P., Xie, K., Sawaya, R. A., & Huang, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1429 · Cited by 93

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Valpione, S., Carlino, M. S., Mangana, J., Mooradian, M. J., McArthur, G. A., Schadendorf, D., Hauschild, A., Menzies, A. M., Arance, A. M., Ascierto, P. A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.007 · Cited by 93

W nt5 A promotes an adaptive, senescent‐like stress response, while continuing to drive invasion in melanoma cells

Webster, M. R., Xu, M., Kinzler, K. A., Kaur, A., Appleton, J., O’Connell, M. P., Marchbank, K., Valiga, A. A., Dang, V. M., Perego, M., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12330 · Cited by 91

Interferon-γ-Mediated Growth Regulation of Melanoma Cells: Involvement of STAT1-Dependent and STAT1-Independent Signals

Bosserhoff, A., Kortylewski, M., Komyod, W., Kauffmann, M.-E., Heinrich, P. C., & Behrmann, I. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22237.x · Cited by 91

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy

Maccalli, C., Parmiani, G., & Ferrone, S. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1280051 · Cited by 90

MITF Modulates Therapeutic Resistance through EGFR Signaling

Ji, Z., Chen, Y. E., Kumar, R., Taylor, M., Njauw, C.-N. J., Miao, B., Frederick, D. T., Wargo, J. A., Flaherty, K. T., Jonsson, G. G., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.105 · Cited by 87

Lighting a path to pigmentation: mechanisms of MITF induction by UV

Liu, J. J., & Fisher, D. E. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00775.x · Cited by 86

Potent Selection of Antigen Loss Variants of B16 Melanoma following Inflammatory Killing of MelanocytesIn vivo

Sanchez-Perez, L. A., Kottke, T. J., Díaz, R. M., Ahmed, A. U., Thompson, J., Chong, H., Melcher, A. A., Holmen, S. L., Daniels, G. A., & Vile, R. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3216 · Cited by 86

Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells

Nam, S., Xie, J., Perkins, A., Ma, Y., Yang, F., Wu, J., Wang, Y., Xu, R.-Z., Huang, W., Horne, D. A., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.05.002 · Cited by 85

Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.

Herlyn, M., Guerry, D., & Koprowski, H. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.4226 · Cited by 83

Expression of SOCS-1, Suppressor of Cytokine Signalling-1, in Human Melanoma

Li, Z., Metze, D., Nashan, D., Müller‐Tidow, C., Serve, H. L., Poremba, C., Luger, T. A., & Böhm, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23408.x · Cited by 83

Antitumor Activities of Interferon Alpha, Beta, and Gamma and their Combinations on Human Melanoma Cells In Vitro: Changes of Proliferation, Melanin Synthesis, and Immunophenotype

Garbe, C., Krasagakis, K., Zouboulis, C. C., Schröder, K., Krüger, S., Stadler, R., & Orfanos, C. E. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12875837 · Cited by 82

Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response

Ugurel, S., Houben, R., Schrama, D., Voigt, H., Zapatka, M., Schadendorf, D., Bröcker, E., & Becker, J. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2682 · Cited by 82

Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinations

Mortarini, R., Belli, F., Parmiani, G., & Anichini, A. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450221 · Cited by 81

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype

Ohanna, M., Cheli, Y., Bonet, C., Bonazzi, V. F., Allegra, M., Giuliano, S., Bille, K., Bahadoran, P., Giacchero, D., Lacour, J. P., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1143 · Cited by 78

Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma

Kumar, D., Gorain, M., Kundu, G., & Kundu, G. C. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0578-3 · Cited by 78

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

Kim, H., Frederick, D. T., Levesque, M. P., Cooper, Z. A., Feng, Y., Krepler, C., Brill, L. M., Samuels, Y., Hayward, N. K., Perlina, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.049 · Cited by 77

A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status

Zipser, M. C., Eichhoff, O. M., Widmer, D. S., Schlegel, N. C., Schoenewolf, N. L., Stuart, D. D., Liu, W., Gardner, H., Smith, P. D., Nuciforo, P. G., et al. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00823.x · Cited by 75

Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy

He, Y., Wang, X., Zhang, G., Chen, H., Zhang, H., & Feng, Z. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0654-1 · Cited by 75

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

Titz, B., Lomova, A., Le, A., Hugo, W., Kong, X., ten Hoeve, J., Friedman, M., Shi, H., Moriceau, G., Song, C., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.28 · Cited by 75

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

Lo, J. A., Fisher, D. E., & Flaherty, K. T. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2274 · Cited by 72

Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines

Respa, A., Bukur, J., Ferrone, S., Pawelec, G., Zhao, Y., Wang, E., Marincola, F. M., & Seliger, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2114 · Cited by 71

Precision Oncology: Between Vaguely Right and Precisely Wrong

Brock, A., & Huang, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0448 · Cited by 71

Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy

Chang, C., Pirozzi, G., Wen, S.-H., Chung, I.-H., Chiu, B.-L., Errico, S., Luongo, M., Lombardi, M. L., & Ferrone, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.676130 · Cited by 69

Clonal cooperativity in heterogenous cancers

Zhou, H., Neelakantan, D., & Ford, H. L. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.028 · Cited by 66

Nonheritable Cellular Variability Accelerates the Evolutionary Processes of Cancer

Frank, S. A., & Rosner, M. R. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001296 · Cited by 65

Senescent Cells in Growing Tumors: Population Dynamics and Cancer Stem Cells

Porta, C. A. M. L., Zapperi, S., & Sethna, J. P. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002316 · Cited by 63

Interferon γ limits the effectiveness of melanoma peptide vaccines

Cho, H.-I., Lee, Y.-R., & Celis, E. (2010) · Blood · doi:10.1182/blood-2010-08-298117 · Cited by 61

Gene Expression Changes and Signaling Events Associated with the Direct Antimelanoma Effect of IFN-γ

Gollob, J., Sciambi, C. J., Huang, Z., & Dressman, H. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1387 · Cited by 61

Both Complexity and Location of DNA Damage Contribute to Cellular Senescence Induced by Ionizing Radiation

Zhang, X., Ye, C., Sun, F. Z., Wei, W.-J., Hu, B., & Wang, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155725 · Cited by 60

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes

Murtas, D., Maric, D., Giorgi, V. D., Reinboth, J., Worschech, A., Fetsch, P. A., Filie, A. C., Ascierto, M. L., Bedognetti, D., Liu, Q., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.335 · Cited by 59

Meta-hallmarks of aging and cancer

López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529

Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunitiesPreprint

Rambow, F., Marine, J., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 348

Pre-clinical modeling of cutaneous melanoma

Rebecca, V. W., Somasundaram, R., & Herlyn, M. (2020) · Nature Communications · doi:10.1038/s41467-020-15546-9 · Cited by 244

The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution

Nirmal, A. J., Maliga, Z., Vallius, T., Quattrochi, B., Chen, A. A., Jacobson, C. A., Pelletier, R. J., Yapp, C., Arias-Camison, R., Chen, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1357 · Cited by 211

Principles and mechanisms of non-genetic resistance in cancer

Bell, C. C., & Gilan, O. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 190

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

Ahmed, F., & Haass, N. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00173 · Cited by 153

Abstract B028: Overcoming resistance by driving melanoma cells into drug-susceptible states

Harmange, G., Emert, B., Schaff, D. L., Hueros, R. A. R., & Shaffer, S. M. (2022) · Cancer Research · doi:10.1158/1538-7445.evodyn22-b028

MITF : More Interesting Traits, Folks!

Kemper, K., Krijgsman, O., & Peeper, D. S. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12476 · Cited by 1

MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming

Kisielewska, M., Suwała, S., Drąg‐Zalesińska, M., & Rembiałkowska, N. (2026) · Cell Cycle · doi:10.1080/15384101.2026.2684937

Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors

Lim, S. Y., Lin, Y., Lee, J., Pedersen, B., Stewart, A., Scolyer, R. A., Long, G. V., Yang, J. Y. H., & Rizos, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105308 · Cited by 11